ClinicalTrials.gg
RecruitingNCT06991348TOP-GERDUpdated Jul 23, 2025

Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole

A Phase 4 interventional study of Tegoprazan and Pantoprazole in Gastroesophageal Reflux Disease, sponsored by Carnot Laboratories. Recruiting at 2 sites in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by Carnot Laboratories · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 9 months after the study started (first participant enrolled Jul 2024, registered May 2025).
  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Gastroesophageal Reflux with a site in Mexico — 3 open to participants now, 3 under way, none of them phase 3. Gastroesophageal Reflux · Mexico.

Planned enrollment
4th of 12
128 · median 83
Started
2024
with 1 other
Phase 4
Only one
of the 14
Registered
14th of 14
by date
Lead sponsor
1 of 14
Carnot Laboratories

Among the 14 studies in Gastroesophageal Reflux with a site in Mexico, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 4, and was the 14th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

3 of the 14 studies in Gastroesophageal Reflux with a site in Mexico are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Gastroesophageal Reflux with a site in Mexico, or all of them as a file.
02

Study summary

The objective of this clinical trial is to compare which of the two drugs best resolves symptoms in patients diagnosed with erosive and non-erosive gastroesophageal reflux disease, adult males and females. The main question is What is the proportion of patients with resolution of the main symptoms of gastroesophageal reflux disease at four weeks of treatment with pantoprazole vs tegoprazan.

03

Conditions studied

  • Gastroesophageal Reflux Disease

Keywords

  • GERD
  • pantoprazole
  • tegoprazan
  • P-CAB
  • PPI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • With endoscopic diagnosis of GERD or NERD (endoscopy ≤ 15 days old)
  • With positive impedance pHmetry results (pHmetry ≤ 15 days old)
  • With recurrent symptoms of heartburn and regurgitation for a previous period ≥ 3 months old

Exclusion criteria

Exclusion Criteria:

  • With known to tegoprazan, pantoprazole, or any of the components of each formulation
  • Subjects with concomitant administration of atazanavir, nelfinavir or rilpivirine
  • Nephropathic and/or hepatopathic subjects (including non-alcoholic hepatitis)
  • Subjects with upper gastrointestinal tract bleeding
  • Subjects with gastric and/or duodenal ulcer 2 months prior to screening
  • Subjects with a history of esophageal or gastric surgery
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Non-erosive GERD - Test product

    Non-erosive GERD - Tegoprazan

    Drug: Tegoprazan

  • Active comparator
    Non-erosive GERD - Comparator

    Non-erosive GERD - Pantoprazole

    Drug: Pantoprazole

  • Experimental
    Erosive GERD - Test product

    Erosive GERD - Tegoprazan

    Drug: Tegoprazan

  • Active comparator
    Erosive GERD - Comparator

    Erosive GERD - Pantoprazol

    Drug: Pantoprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with resolution of the main symptoms of gastroesophageal reflux disease

    Carlsson-Dent Questionnaire. These tool consists of 7 multiple-choice questions, using a cut-off point ≥ 4 to be considered positive, which qualitatively assesses symptoms associated with GERD and triggering factors such as diet, posture and medications used.

    Time frame: From enrollment to the end of treatment at 4 weeks

07

Study locations

2 of 2 sites recruiting
  • Gastrologen S.A. de C.V.
    Mexico City, Mexico City 01900, Mexico
    Recruiting
    • Luis R Valdovinos-Garcia, Dr · Contactdrprapul@gmail.com · +52 (55) 6464 4227
    • Luis R Valdovinos-Garcia, Dr · Principal investigator
  • Saluz Investigación, S.C.
    Boca del Río, Veracruz 94299, Mexico
    Recruiting
    • Jose M Remes-Troche, Dr · Contactjose.remes.troche@gmail.com · +52 (229) 921 8869
    • Jose M Remes-Troche, Dr · Principal investigator
08

References and documents

Publications

  • Cho YK, Kim JH, Kim HS, Kim TO, Oh JH, Choi SC, Moon JS, Lee SK, Jung SW, Kim SS, Jung HK, Lee SP, Cheon GJ, Park MI, Jung HY, Ko KH, Sung IK, Lee SH, Lee JY, Lee ST, Rhee PL, Kim N, Hong SJ, Kim HJ, Kim GH, Lee KJ, Kim SK, Shin WG, Lee OY. Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis. Aliment Pharmacol Ther. 2023 Jan;57(1):72-80. doi: 10.1111/apt.17255. Epub 2022 Oct 31. PubMed 36314172 ↗

Individual participant data

Plan to share: No — Only IPD used in the results publication

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Nov 2025, 16 months after the start.

Of 30 phase 4 interventional studies under Gastroesophageal Reflux, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
May 27, 2025
StartActual
Jul 30, 2024
Primary completionEst.
Nov 30, 2025
CompletionEst.
Nov 30, 2025
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06991348
Lead sponsor
Carnot Laboratories
Responsible party
Sponsor
First posted
May 27, 2025
Start date
Jul 30, 2024
Primary completion
Nov 30, 2025 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Jul 23, 2025

Study contacts

Jose M Remes-Troche, Dr
principal investigator · Digestive Physiology and Motility Lab, Instituto de Investigaciones Médico Biológicas, Veracruz , México

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprazan

Start the discussion